Meet Allozymes! This Singapore-based biotech has built their own game-changing  technology that allows you to build and test millions of enzymes—sustainably and at scale.

Now, they’ve just raised a $15M Series A!

Investor check. Investors include Seventure Partners, NUS Technology Holdings, Thia Ventures, and ID Capital. Xora Innovation, SOSV, Entrepreneur First, and Transpose Platform also joined in!

• They last raised a $5M seed in 2021.

‍

🧪 From hundreds to millions

There are billions of variations of enzymes. And with traditional methods, a couple hundred can be tested a day in a lab.

But with Alloyzmes’ methods, you could build and test millions of enzymes a day.

It’s a big deal. Biotech and chemical companies are heavily reliant on enzymes to do many processes. Think creating ingredients, chemicals, and more.

• But it’s tough for them to find a cheap and effective one quickly.
• So, they constantly test enzymes in a slow, polluting, and unscalable process.

‍

👨🏻‍🔬 What they do

SingZyme. Right now, most of the work they do is around finding a single enzyme.

• It’s for companies saying, we want to do this 100x faster or cheaper.

MultiZyme. In the future, they’ll be discovering or refining multiple enzymes at a time.

• It’s for companies saying “we need an enzyme that does this”.

‍

🔢 Data, data

As they test millions of enzymes a day, they’ll start growing a dataset and be able to screen through it with AI and ML to develop new solutions

• These will be their own IP and aims to become the biggest enzyme data library in the world.

‍

🔜 What’s next?

They’ll be expanding to Europe and making strategic partnerships in related sectors. Plus, they’ll be building up their internal expertise and processes to push for efficiency.

• They may fundraise again to expand into pharmaceuticals and to the US market.